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The oxygen-labile hemolysin of Streptococcus  pyogenes,  or a substance having 
properties closely resembling those of this hemolysin, has an acute action on 
the  isolated frog's heart (1).  The most interesting feature of the action of this 
substance is that a  single application of the toxin is essentially without effect 
on the heart, while a  second application of the same preparation, given after 
washing  the  heart  with  two portions of Ringer's solution,  results almost im- 
mediately in systolic standstill.  That the phenomenon described consists of a 
true  sensitization 1 of  the  heart  to  streptococcal  toxin,  and  not  of  a  simple 
summation of two subthreshold doses of the toxin, is shown by the fact that a 
single dose is without specific effect even when it is many times greater than 
the  dose required  to produce systolic contracture  of a  sensitized heart.  The 
mechanism  of  the  sensitization  has  been  investigated  and  the  results  are 
reported in  the present  communication. 
EXPERIMENTAL 
The methods employed were those used previously (1).  The term, SPA, is employed to 
denote "streptococcal preparation A,"  a  dialyzed and  concentrated culture  supernate the 
preparation of which is described in (1).  The streptococcal preparation was activated with 
cysteine prior to application to the heart. 
1.  Demonstration that the Heart Releases  an Inhibitor  to SPA.--Exploratory 
experiments indicated that the heart might release an SPA inhibitor in response 
to a  single application of activated  SPA.  This possibility was tested  in  the 
following experiment: 
Ringer's solution containing SPA in a concentration of 1:250  and cysteine in a concentra- 
tion of 1:2500  was introduced into the Ftihner cannula.  The only effect, as has previously 
been reported (1),  was a  slight increase in amplitude of contraction.  After 5 minutes, the 
1 The word "sensitize" is not intended to connote sensitization in the immunological sense, 
but is here employed in accordance with general biological usage, that is, to render susceptible 
or responsive. 
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fluid was removed from the heart, designated "A," and kept at room temperature.  The heart 
was washed twice with Ringer's solution.  After 10 minutes a solution containing SPA in a 
concentration of 1:125 and cysteine in a concentration of 1:1250 was mixed with an equal 
volume of "A," and the mixture applied to the heart.  The solution had no effect other than 
a slight increase in amplitude of contraction.  After 3 minutes, the fluid was removed and 
the heart was washed with two portions of Ringer's fluid.  Application of a control solution 
containing SPA in a concentration of 1:250 and cysteine in a concentration of 1:2500 pro- 
duced complete systolic standstill within 30 seconds (Fig. 1). 
The  experiment  presented  in  Fig.  1  has  been  repeated  numerous  times, 
always with the same result, the release of an inhibitor. 
FIG. 1. Inhibition of cardiotoxic effect of SPA by a substance released from the isolated 
frog's heart (Straub), suspended on Ftihner's cannula:  Ringer's solution 1.2 cc.  Kymographic 
record of amplitude of ventricular contraction.  At arrows, SPA 1:250 in cysteine 1:2500. 
At A, fluid was removed from the heart, labeled "A," set aside, and Ringer's solution applied 
to the heart.  At B, SPA 1  : 125 in cysteine 1  : 1250 mixed with an equal volume of "A."  R, 
washing with Ringer's solution.  Figures indicate in minutes the period of arrest of the drum. 
In order to determine whether the release is specifically associated with the 
administration of the first, or sensitizing, dose of activated SPA, the following 
solutions were tested for inhibitory activity: (1)  Ringer's solution which had 
bathed  normal hearts;  (2)  Cysteine 1:2500  in Ringer's  solution; (3)  Heat- 
inactivated SPA  1:100  and  cysteine  1:2500  in  Ringer's solution.  Each  of 
these three solutions was applied to different hearts for 5 minutes, at the end 
of which time the solutions were removed from the hearts and tested.  In no 
instance did these solutions, when mixed with a second dose of activated SPA, 
prevent the development of systolic contracture (Table I). 
The escape of an inhibitor from the heart upon application of the first dose 
of the toxin can account for the sensitization described in the preceding paper. 
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release from  the heart of an inhibitor, one would not expect to find released 
inhibitor from hearts  which  had  undergone  systolic standstill in  response  to 
the second dose of activated SPA.  Fluid was removed from hearts that had 
undergone  contracture  in  response  to  a  second  (or  "contracturing")  dose of 
SPA  1:250 with cysteine 1:2500,  designated "B,"  and was tested in another 
heart for capacity to prevent the contracturing action of a solution of SPA in a 
final concentration  of  1:250  with  cysteine  1:2500.  The  solution designated 
"B"  was found not to possess inhibitory activity. 
In summary, the above experiments demonstrate conclusively that the heart 
responds to a  single dose of SPA by releasing a  substance which inhibits the 
TABLE I 
Synopsis  of Kymograph  Tracings Demonstrating that SPA  Inhibitor  Is  Rdeased  from  the 
Heart upon Administration  of SPA 
Solution administered to sensitized heart* 
A.  SPA 1:250 +  cysteine 1:2500 .................. 
B.  A containing inhibitor fluid 1:2 ................. 
C.  A containing inhibitor fluid 1:5 ................. 
D.  A containing inhibitor fluid 1 : 10 ................ 
E.  A containing normal heart washing 1:2~ ......... 
F.  A containing heated SPA 1:250§ ................ 
G. A  containing  fluid  taken  from  heart  in  con- 
tracture I : 2 ................................ 
Effect 
Systolic contracture 
No effect 
No effect 
Partial systolic contracture 
Systolic contracture 
Systolic contracture 
Systolic contracture 
* Isolated frog's heart (Straub) sensitized to SPA by administration of Ringer's solution 
containing SPA 1: 250 and cysteine 1 : 2500, followed by washing with two portions of Ringer's 
solution. 
:~ Normal heart washing indicates Ringer's solution which had bathed  a normal isolated 
heart for 5 to 15 minutes. 
§ Heated SPA indicates SPA heated to 70  ° C. for 10 minutes followed by administration 
(with cysteine 1 : 2500) to a normal isolated heart for 5 minutes. 
action  of  the  toxin.  For  convenience  of presentation,  the  substance  which 
inhibits systolic contracture  will be  referred to  as  "inhibitor,"  and  the fluid 
containing it, "inhibitor fluid." 
The  capacity  of  the  inhibitor  fluid  to  prevent  systolic  contracture  was 
measured  by  mixing  a  series  of  dilutions  of  inhibitor fluid with  a  constant 
contracturing dose of activated SPA, and by applying these mixtures ~o hearts 
previously sensitized.  Although  the potency of the inhibitor fluid from dif- 
ferent hearts seemed to vary somewhat,  in general the contracturing dose of 
SPA was inhibited by a  fivefold but not by a  tenfold dilution of the inhibitor 
fluid  (Table I). 
2.  Neutralization  of Lethal  Activity  of SPA.--Several  investigators  (Parish 
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demonstrated the existence of lethal factors in concentrated or unconcentrated 
filtrates and supernates of cultures of hemolytic streptococci.  The preparation 
of SPA used in the present study was found to contain a  lethal factor.  When 
injected intravenously, 0.01  to 0.02 cc. of activated SPA caused mice weighing 
16 to 20 gm. to die within 2 or 3 hours after injection.  Death was frequently, 
but not always, preceded by the outpouring from the nostrils of hemoglobin- 
tinged fluid. 
In the preceding section it was shown that a  substance released by the heart 
upon administration of SPA is capable of inhibiting the  contracture-inducing 
TABLE II 
Inhibition  of Lethal Aaidty of SPA by Fluid Obtained  from Frogs' Hearts Which Had 
Been Treated with SPA 
Experimen- 
tal mice 
Control mice 
Inhibitor 
fluid 
cc. 
0.50 
0.25 
0.125 
Content of mixture injected 
Normal 
heart  SPA 
washing 
CC,  CO. 
--  0.02 
--  0.02 
--  0.02 
O.5  O.O2 
--  0.02 
--  0.02 
Saline 
CC, 
0.48 
0.73 
0.855 
0.48 
0.98 
0.48 
No. of mice 
injected 
No. of mice 
which 
survived* 
6~ 
5 
4§ 
* Mice which survived less than 5 minutes were counted as deaths.  Unless  otherwise 
noted  mice which survived 5 minutes remained alive for the 1 week period during which 
they  were kept under observation. 
:~ 2  died overnight. 
§ 3  died overnight. 
action of the toxin.  It was of interest to see whether the inhibitor fluid  was 
capable of neutralizing the lethal activity of the SPA. 
The test dose of activated SPA was that amount which uniformly killed 16 to 20 gm. mice 
within 5 minutes after intravenous injection, namely 0.5 cc. of a 1:25 dilution of SPA.  Vari- 
ous amounts of inhibitor fluid from the frog's heart were mixed with a constant quantity of 
activated SPA, and the mixtures were injected intravenously into mice  (Table II).  Of a 
total of 17 mice which received from 0.125 to 0.50 cc. of inhibitor fluid and 0.02 cc. of SPA in 
a final volume of 1 ce., 15 survived longer than 5 minutes.  Of these 15, ten survived indef- 
initely.  All of the eleven control mice which received no inhibitor died within 5 minutes. 
The  antilethal potency  of the  inhibitor fluid  appeared  to  be  of  the  same 
order as its capacity to protect against the cardiotoxic action of the SPA. 
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nature  of  the  inhibitor,  some  of  its properties  were  studied.  Isolated  hearts 
were exposed  to a  single dose of SPA  1:100  to  1:250,  activated  with  cysteine 
1:2500,  and  after  5  minutes  the  fluid  was  removed.  The  quantity  of  fluid 
obtained  from  each  heart  was  approximately  1.2  cc.  The  inhibitor  fluid 
collected  from  8  to  12  hearts  was  pooled  and  stored  in  the  refrigerator  until 
used. 
Heat Stability.--A  tube  containing several cubic centimeters  of inhibitor fluid was  im- 
mersed in water at 70  ° C. for 10  minutes.  The capacity of the heated  fluid to inhibit the 
TABLE  III 
Thermolability, Dialyzability,  and Solubility  in Chloroform of Inhibitor Fluid  Obtained from 
the Isolated Frog's Heart after Exposure to a Single Dose of SPA Activated witk Cysteine 
Test solution 
Untreated inhibitor fluid .......... 
Inhibitor fluid  heated  to  70°C.  for 
10 rain  ........................ 
Dialyzable fraction of inhibitor fluid. 
Non-dialyzable fraction of inhibitor 
fluid .......................... 
CHClrextractable fraction of inhibi- 
tor fluid ....................... 
Residue from CHCh extraction .... 
Inhibition of lethal action of SPA.* 
Effect of intravenous injection of test 
solution -b 0.02 cc. of SPA in mice 
0.25 cc. protected each of 3 mice 
0.25 cc. protected each of 3 mice 
0.50 cc. protected none of 3 mice 
0.25 cc. protected each of 3 mice 
0.50 cc. protected each of 2 mice 
0.50 cc. protected neither of 2 mice 
Inhibition of 
contracturing 
action of SPA.$ 
Effect on the 
isolated frog's 
heart of 
test solution 
-b a contrac- 
turlng dose 
of SPA 
Inhibited 
Inhibited 
Failed  to 
inhibit 
Inhibited 
Inhibited 
Failed to in- 
hibit 
* Inhibition of lethal action of SPA was tested in the manner illustrated in Table II. 
Inhibition of contracturing action of SPA was tested in the manner of Table I. 
contracturing action of SPA was then compared to that of unheated inhibitor fluid.  In addi- 
tion to testing for inhibition of cardiotoxic action of SPA, the capacity of the heated inhibitor 
fluid to prevent the lethal action of SPA in mice was also tested.  The  results of this experi- 
ment are presented in Table III, in which it can be seen that heating to 70  ° C. for l0 minutes 
did not reduce the anticontracturing potency nor the antilethal action of inhibitor fluid.  In 
similar experiments, more drastic treatment, namely heating the inhibitor fluid in boiling water 
for 30 minutes, did not reduce appreciably the anticardiotoxic action.  The factor responsible 
for inhibition of SPA is therefore relatively heat-stable. 
Non-Dialyzability.--3.S  cc.  of inhibitor fluid were dialyzed in a  cellophane sac  (Visking 
Corporation) against 7 cc. of Ringer's solution.  Dialysis was carried out in the cold with 
occasional agitation over a  period of 96 hours.  At the end of this time, the anticardiotoxic 
action and the antflethal activity of the residue and of the dialysate were tested.  All of the 
inhibitory activity was  found  to  be present in the residue  (Table III).  This experiment 
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Solubility in Chloroform.--3  cc. of inhibitor fluid were shaken at room temperature with 
five 3 co. portions of chloroform.  A relatively large amount of precipitate formed at the chlo- 
roform-Ringer  interface after extraction with the first portion of chloroform.  The precipitate 
was separated, dissolved in saline solution, and tested for inhibitory activity.  As this frac- 
tion failed to inhibit either the cardiotoxic or lethal actions of SPA, it was discarded.  The 
combined chloroform  extracts were concentrated to 1.5 co. in vacuo, and the concentrate was 
added dropwise to 3 co. of boiling saline solution.  After  adjusting the volume, the resulting 
suspension was tested in the frog's heart and in mice, and was found to inhibit both cardiotoxie 
action and lethal effect of SPA.  The aqueous fraction remaining after chloroform  extraction 
failed to inhibit either of these actions (Table III).  This  experiment shows that the inhib- 
itory activity can be recovered from the chloroform-soluble  fraction. 
DISCUSSION 
The  present  results  not  only  afford  an  explanation  of  the  sensitization 
described  in  the  preceding paper but  in  addition permit  the  formulation of 
the probable sequence of events which follows exposure of the isolated frog's 
heart  to  the  streptococcal  toxin.  Although  the  administration  of  a  single 
dose of diluted streptococcal toxin does not result in a persistent visible change 
in the functioning of the isolated frog's heart, it causes an effect the existence 
of which is not immediately obvious.  This effect consists in the outpouring 
into the fluid which bathes the heart, of a substance which is capable of combin- 
ing with the toxin, and of preventing further damage.  The release of inhibitor 
is relatively rapid, and the quantity released by the heart is greatly in excess 
of that required to neutralize the toxin which is applied.  Washing the toxin- 
treated  heart with  two portions of Ringer's solution  removes practically all 
of the  inhibitor,  and leaves an inhibitor-free organ whose state  of reactivity 
differs markedly from that of the normal heart.  Because it lacks the inhibitory 
substance,  the  "sensitized"  heart  responds  acutely  to  the  application  of  a 
second dose of streptococcal toxin; the response consists in the rapid develop- 
ment of systolic contracture. 
The mechanism of the sensitization described is not without analogy.  Clark 
(7)  has  shown  that  after  perfusion for a  few hours  the  excised frog's heart 
passes into a hypodynamic state.  This condition is interpreted as being due 
to sensitization of the heart to Na and K  ions present in the Ringer's solution, 
as  can be  seen  by the  prompt  recovery of the heart  upon decrease  in  the 
CK  + -~- CNa+ 
of the perfusion fluid.  In the hypodynamic  condition, the 
Cca++ 
heart becomes more sensitive to alterations in the ionic balance of the perfusion 
fluid.  The  similarity  between  the  sensitization  investigated  by  Clark  and 
that  discussed here  is  further illustrated  by the  fact that  in  both  cases the 
change in  the state  of the heart is associated with  the loss of certain tissue 
constituents.  In  the  case  of  the  hypodynamic heart  the  constituents  have 
been shown by Clark to be lipids; in the case described herein the constituents 
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in the manner and rapidity with which  the  sensitized state is induced.  The 
hypodynamic condition develops slowly and is apparent only after prolonged 
washing, while the  sensitization caused by the  streptococcal  toxin develops 
in a  matter of seconds. 
The rapid liberation from the heart of a substance which inhibits the action 
of a bacterial toxin appears to have no counterpart in the well studied phenom- 
ena of immunity.  The stability of the inhibitor toward heat and its solubility 
in chloroform are properties which  clearly set it apart from antibody in the 
usual sense of the term.  The present observations may find some analogy 
in the early observations of Pohl (8)~ Hueck (9), Waeker and Hueck (10), and 
K6hler (11)  on the type of immunity induced by the repeated injection into 
animals of sublethal  doses of saponin.  The increased saponin tolerance of 
animals  treated  in  this manner, has been  attributed  to  increased formation 
of cholesterol. 
SUMMARy 
1.  The mechanism of sensitization of the isolated frog's heart to a product 
of  the  hemolytic  streptococcus  has  been  investigated.  The  sensitization 
depends upon the release from the isolated heart of a substance which inhibits 
the action of the cardiotoxin.  The inhibitor is released upon the first (sen- 
sitizing) administration of cardiotoxin, but not upon the second (contracture- 
producing) administration. 
2.  The inhibitor released by the heart neutralizes the lethal factor present 
in the streptococcal preparation employed. 
3.  Some of the properties of the inhibitor have been investigated. 
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